Navigation Links
Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes
Date:6/18/2013

LAVAL, Quebec, June 18, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (the "Company") announced today that VPII Escrow Corp., a newly formed wholly owned Canadian subsidiary of the Company, has launched its offer of approximately $3.2 billion aggregate principal amount of senior unsecured notes (the "Notes").  The Notes will be due in 2021 and in 2023, with final tranching determined at pricing.

The Company intends to use the net proceeds from the offering, together with proceeds from its previously announced public offering of common shares and other debt financing, to fund (i) the consideration of its previously disclosed acquisition (the "Merger") of Bausch + Lomb Holdings Incorporated ("B+L"), (ii) the fees and expenses incurred in connection with the Merger; and (iii) the repayment or retirement of B+L's outstanding debt.

The Notes will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.

Forward Looking Statements

This press release may contain forward-looking statements, including, but not limited to those related to the Company's intended use of proceeds, the anticipated tranching of the Notes and the acquisition and financing of B+L. Forward looking statements can generally be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "should," "would," "intend," "seem," "potential," "appear," "continue," "future," believe," "estimate," "forecast," "project," variations of such words or other words that convey uncertainty of future events or outcome, although not all forward-looking statements contain these identifying words. Our forward-looking statements are subject to known and unknown risks and uncertainties, many of which are outside of our control and could cause actual results to differ materially and adversely from those expressed or implied by such statements. Those risks include, but are not limited to: our future economic performance, operating results, financial condition, capital resources or prospects; projections of revenue, expenses, income and losses, earnings (losses) per share, capital expenditures, dividends, growth rates or other financial items; market or industry trends, legal or regulatory developments; future events; the anticipated effect of acquisitions, litigation, new (or changes to existing) laws, regulations or accounting principles or other matters on our business, economic performance, operating results, financial condition, capital resources or prospects; our plans, objectives and strategies for future operations or otherwise; and our expectations and beliefs. Information concerning potential factors that could affect the Company's financial results is included in the Company's most recent annual or quarterly report and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com  


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Prices Public Offering Of Common Shares
2. Valeant Pharmaceuticals Announces Public Offering Of Common Shares
3. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
4. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole
5. Valeant Pharmaceuticals Announces 2013 Annual Meeting Results
6. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
7. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
8. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
9. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
10. Valeant Pharmaceuticals Provides Efinconazole Update
11. Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Research and Markets has announced the addition of ... & Biochemical Research, Disease Diagnostics), End User (Academic & Research Institutes, ... to their offering. ... , The western blotting market ... 574.8 Million in 2016, growing at a CAGR of 4.9%. ...
(Date:12/5/2016)... 5, 2016   BIOTRONIK today announced the ... study evaluates the safety and feasibility of performing the ... setting. BioMonitor 2 is an insertable cardiac ... placed underneath a patient,s skin to help physicians accurately ... fibrillation is a leading cause of stroke and heart ...
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
Breaking Medicine Technology:
(Date:12/6/2016)... , ... December 06, 2016 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:12/6/2016)... ... 06, 2016 , ... U.S. Security Associates (USA) was named ... their industry leading training methods that engage their associates and link their achievements ... elite in employer-sponsored training and development programs. , “The 2017 Training Top 125 ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... its latest transitional care facility – Avamere Transitional Care of Puget Sound ... foot short-term, post-acute health care center will provide patients recovering from illness or ...
(Date:12/5/2016)... St. Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... effects concussions have on the growing brains of young athletes. Over the course of ... to the head through unique mouth guards. The mouth guards, equipped with special sensors, ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
Breaking Medicine News(10 mins):